Stay up to date with the latest news and activities at AKESOgen.

AKESOgen to host the 1st Inaugural In-situ Hybridization, Microarray & Next-Generation Sequencing in Clinical Diagnostics Symposium together with Targos and the National Society of Histotechnology

AKESOgen-Logo333         Unknown              targos logo

AKESOgen, a leader in personalized medicine and genomics, has partnered with Targos and the National Society of Histotechnology to create and assemble an inaugural course on In-situ Hybridization, Microarray & Next-Generation Sequencing in Clinical Diagnostics.  The course will be held at the Emory conference center on Oct 26th-28th, 2015.  Please click the link below to view the provisional agenda.  Additionally, the course will provide CEU credits.

NSH Molecular Course Outline October 26-28 2015

About AKESOgen, Inc. 

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

About the National Society of Histotechnologists

NSH is the premier source of learning, knowledge and future-oriented research for histology professionals. Attendance provides resources, education, ideas and advocacy to enhance the performance in the laboratory and ultimately the best patient care.

http://www.histoconvention.org/

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

CYP19A1 polymorphisms and clinical outcomes
in postmenopausal women with hormone receptor-positive
breast cancer in the BIG 1–98 trial

Leyland-Jones B1, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell’Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ,Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

PMID:24814193

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
ICB logo-Shanghai

AKESOgen’s CSO to deliver plenary lecture at the third annual International Conference on Biomarkers Discovery and Clinical Application, Shanghai, China

Shanghai, China- 17th-18th October, 2015- Personalized medicine and genomics company, AKESOgen, has been invited to attend and speak at the third annual International Conference on Biomarkers Discovery and Clinical Application (ICB) in Shanghai, China  as an industry expert on genomic profiling in multiple cancers.  The ICB will bring together international pharmaceutical, biotech and diagnostics companies, leading universities and institutions, healthcare, government, and national labs, CROs and tool providers.  The third annual ICB will focus on the following:

  • Trends in Biomarker Research
  • Biomarkers and translational medicine
  • Biomarkers in drug development
  • Innovation in biomarker discovery

“International conferences such as the ICB marks the impact that genomic information, shared internationally, can provide to improving precision medicine” said Mark Bouzyk, CSO of AKESOgen.

ICB logo-Shanghai           AKESOgen-Logo333

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen to host and sponsor Industry tour on behalf of Georgia Bio

Please join Georgia Bio’s Emerging Leaders Network on their Industry Tour for an inside look of AKESOgen, a premier provider of genetic analysis.

This industry tour will provide participants an inside look of AKESOgen, a leader in personalized medicine and genomics.  Equipped with industry experts, AKESOgen provides high quality genomic analysis services, performing over 21,000 whole genome genotyping monthly. It is the only facility in the United States that has developed and performs clinical commercial copy number alteration (CNA) microarray analysis for formalin-fixed, paraffin-embedded (FFPE) tissue samples on Illumina platforms. AKESOgen provides contract research, clinical diagnostic and clinical trial services to pharmaceutical, biotech, academic, and government research institutions.  The company supported over 100 academic investigators in 2014.

All participants should be dressed smart casual with closed toe shoes.

To register for this event and further details please go to: http://www.gabio.org/events/event_details.asp?id=600212

When:
Wednesday, September 09, 2015
10:30 am – 12:30 pm

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

2014 BioGENEius Winner Kayla Evans Visits AKESOgen

February, 11, 2015 - The 2014 Georgia BioGENEius Winner, Kayla Evans visited Georgia Bio AKESOgen.

The visit began with an introduction of the company and then the small group including Ms. Evans and her parents, and Georgia BioEd Institute Program Director, Melissa Nikolic, proceeded to tour the facility. Ms. Evans learned about opportunities in the life sciences field and heard from AKESOgen employees about the research and technology at the company.

The BioGENEius Challenge is the premier competition for high school students that recognizes outstanding research in biotechnology.  It promotes excellence and enables students to continue research in biotechnology and design an original independent research project.  Applications are now being accepted for the 2015 Challenge. Click here to learn more.

AKESOgen were delighted to sponsor Ms. Evans attendance and presentation at the Georgia Bio Awards Dinner on January 22, 2015. 

IMG_0187

Pictured: Mark Bouzyk Ph.D. Co-Founder & CSO, AKESOgen; Kayla Evans; and Melissa Nikolic, Georgia BioEd Institute Program Director

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen receives a prestigious Deal of the Year Award at the Annual Georgia Bio Awards Night

IMG_2374

AKESOgen receives a prestigious Deal of the Year Award at the Annual Georgia Bio Awards Night

Atlanta, USA – 22nd January 2015– AKESOgen was recognized by its peers from the Biotechnology industry at a gala event at the Fox Theatre in Atlanta for its public/ private partnership alliance and outstanding work with the US Department of Veteran’s Affairs.

“We are delighted to be honored by our peers and are particularly proud to be chosen amongst a stellar group of organizations that are true world leaders in the global market and are great examples of the thriving biotechnology community in the state of Georgia” said Bob Boisjoli, CEO of AKESOgen.

The US Department of Veterans Affairs Million Veteran Program is the largest genetic initiative ever undertaken in the US and its visionary genomics and genetics approach will provide new insights about how genes affect health. The goal is to improve healthcare for veterans by understanding the genetic basis of many common conditions. The data will ultimately be beneficial to the healthcare of all veterans and of the wider community.

“We are extremely excited to support the VA for this unique endeavor as we provide genetic data of the highest quality to the VA. AKESOgen is delivering over 800,000 genetic datapoints to the VA for each of the patients it provides analysis making up many terabytes of information each year” commented Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, sequencing, genotyping, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Georgia Bio (www.gabio.org) is the private, non-profit association whose members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Maria Thacker, VP of Operations. Georgia Bio. +1 404-920-2042 (office), or maria.thacker@gabio.org

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
SBC Logo

Shanghai Biotechnology Corporation and AKESOgen form Alliance to Provide Transnational Genomics Services

Partnership will enable and enhance standardized American-Asian protocols

Shanghai, CN and Atlanta, USA – 13th January, 2015–.  Shanghai Biotechnology Corporation (SBC), a leader in Customer-oriented R&D biomarker service provider, and AKESOgen, a respected genetics, genomics and bio repository services provider, announced they will form a strategic business development alliance which will enable joint projects with pharmaceutical and biotechnology clients in the USA and Asia.  The partnership will bring together AKESOgen´s proprietary know-how in sequencing, genotyping, methylation profiling, expression profiling, PCR, qPCR, copy number variation and DNA and RNA extractions, with SBC’s extensive expertise in performing comprehensive genomic and pharmacogenomic services.

“Shanghai Biotechnology Corporation’s services are very complimentary to AKESOgen’s.  This partnership will allow us to jointly develop important opportunities that span the Asian and US genomics markets” said Bob Boisjoli, CEO of AKESOgen.

Dr. Huasheng Xiao, CEO of Shanghai Biotechnology Corporation commented, “AKESOgen and its team of world class experts in the field of genomics are a natural fit for SBC to enhance our service offerings and presence in the US market.”

About Shanghai Biotechnology Corporation

SBC is a leading Chinese global biotech service provider in genomic and genetic biomarker discovery and development.  The core service business of SBC is to provide highly standardized development and application of genomics/genetics biomarkers for the international pharmaceutical and diagnostic industry. The company has supported thousands of R&D projects for pharma, biotech and academia since 2001. SBC has multidisciplinary teams experienced in obtaining, integrating and analyzing complex data using the most advanced technology to explore the role of genetic variation in individual responses to drugs and susceptibility to certain diseases. For more information, visit http://www.shanghaibiotech.com/

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Yuhua Li, MD PhD, Shanghai Biotechnology Corporation. +86-21-51320288, ext 8219 (office), or yuhua_li@shbiochip.com

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

 

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
tricon

AKESOgen attends Molecular Med TRI-CON 2015

Scientists from AKESOgen attended at the Moscone North Convention Center, San Francisco, CA from February 15-20, 2015. Please email info@akesogen.com or call 770 542 0890 if you want to follow up with a delegate.

images

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail